Table 1.
Patient Characteristics
| Characteristic | Prior to order set N = 8,429 (32%) | Following order set N = 17,635 (68%) | Significance (p value) |
|---|---|---|---|
| Age, years | |||
| Mean (SD) | 59 (19) | 59 (19) | 0.84 |
| Male, n (%) | 3,613 (42.9) | 7,774 (44.1) | 0.06 |
| Race, n (%) | <0.001 | ||
| White | 4,601 (54.6) | 9,372 (53.1) | |
| Black | 1,262 (15.0) | 2,489 (14.1) | |
| Asian | 1,462 (17.3) | 3,168 (18.0) | |
| Other | 1,104 (13.1) | 2,606 (14.8) | |
| Hispanic (any race), n (%) | 708 (8.4) | 1,580 (9.0) | 0.14 |
| Medicine or cardiology service, n (%) | 5,910 (70.1) | 12,403 (70.3) | 0.72 |
| Admission from ED, n (%) | 4,984 (59.1) | 10,630 (60.3) | 0.08 |
| Public or No Insurance, n (%) | 4,982 (59.1) | 10,237 (58.1) | 0.11 |
| Elixhauser comorbidities, n (%)* | |||
| Congestive heart failure | 710 (8.4) | 1,350 (7.7) | 0.032 |
| Cardiac arrhythmia | 1,173 (13.9) | 2,719 (15.4) | 0.001 |
| Valvular disease | 373 (4.4) | 1,015 (5.8) | <0.001 |
| Other neurological disorders | 507 (6.0) | 1,021 (5.8) | 0.47 |
| Chronic pulmonary disease | 1,303 (15.5) | 2,805 (16.3) | 0.095 |
| Diabetes without complications | 1,534 (18.2) | 2,805 (15.9) | <0.001 |
| Hypothyroidism | 770 (9.1) | 1,802 (10.2) | 0.006 |
| Renal failure | 946 (11.2) | 2,615 (14.8) | <0.001 |
| Liver disease | 554 (6.6) | 1,335 (7.6) | 0.004 |
| Metastatic cancer | 542 (6.4) | 1,253 (7.1) | <0.001 |
| Coagulopathy | 371 (4.4) | 1,245 (7.1) | <0.001 |
| Weight loss | 262 (3.1) | 1,207 (6.8) | <0.001 |
| Fluid and electrolyte disorders | 1,511 (17.9) | 4,401 (25.0) | <0.001 |
| Deficiency anemias | 1,248 (14.8) | 3,569 (20.2) | <0.001 |
| Drug abuse | 496 (5.9) | 989 (5.6) | 0.37 |
| Depression | 715 (8.5) | 1,884 (10.7) | <0.001 |
| Hypertension | 3,707 (44.0) | 7,806 (44.3) | 0.67 |
| Patient subgroups, n (%)** | <0.001 | ||
| Likely benefit from VTEP | 3,865 (45.9) | 8,365 (47.4) | |
| Unclear benefit from VTEP | 3,541 (42.0) | 6,826 (38.7) | |
| Potential Harm from VTEP | 1,023 (12.1) | 2,444 (13.9) | |
ED = emergency department. VTEP = venous thromboembolism pharmacoprophylaxis
*Only comorbidity measures with an overall prevalence of 5% or more are listed here (17/30)
**Average of the five imputed data sets. Ranges are 3,859–3,871 (likely benefit, prior to order set); 8,361–8,369 (likely benefit, following the order set); 3,536–3,546 (unclear benefit, prior to order set); 6,822–6,830 (unclear benefit, following the order set); 1,015–1,032 (potential harm, prior to order set); 2,438–2,452 (potential harm, following the order set)